-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Special Education Session on Clinical Applications of Newly Approved Drugs

Program: Special-Interest Sessions
Saturday, December 5, 2015: 9:30 AM-11:00 AM
Tangerine 2 (WF2), Level 2 (Orange County Convention Center)
Chair:
Mikkael A. Sekeres, MD, MS, Cleveland Clinic

Disclosures:
Sekeres: Celgene Corporation: Membership on an entity’s Board of Directors or advisory committees ; TetraLogic: Membership on an entity’s Board of Directors or advisory committees ; Amgen: Membership on an entity’s Board of Directors or advisory committees .
The Society’s acclaimed webinar series on newly approved drugs will be continued as a live session at the 2015 ASH Annual Meeting. The session’s didactic presentations will feature a selection of hematologic drugs newly approved in 2015. Presenters will have significant clinical experience with the new agents. The focus of the session will be on issues clinicians face in treating patients with the new drugs: appropriate population, dosing, side effects, adverse events, drug/drug interactions, and off-label use. The didactic presentations will be short—approximately 15 minutes in length—and leave time for audience questions.
Idarucizumab

Kenneth A. Bauer, MD

Beth Israel Deaconess Medical Center, Boston, MA
Blinatumomab

Anjali S. Advani, MD

Leukemia Program, Cleveland Clinic, Cleveland, OH
Panobinostat

Sagar Lonial, MD

Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA; Winship Cancer Institute of Emory University, Department of Hematology and Medical Oncology, Atlanta, GA
See more of: Special-Interest Sessions
<< Previous Session | Next Session >>